Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.
Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, Tsushima T, Hirao M, Tsuda M, Hino K, Yamamoto N, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Ooki A.
Oshima T, et al. Among authors: yasuda k.
BJC Rep. 2024 Sep 4;2(1):66. doi: 10.1038/s44276-024-00066-6.
BJC Rep. 2024.
PMID: 39516370